Current concepts in the diagnosis and management of left ventricular assist device infections

Left ventricular assist devices (LVAD) are increasingly being used both as a bridge to transplantation and for long-term myocardial surrogate destination therapy in patients with end-stage heart failure. Primarily owing to the presence of a driveline that connects the device to an external battery through an open skin incision, the rates of LVAD-related infections (LVADRIs) are high, ranging from 30 to 50%. LVADRIs can be broadly classified into driveline infection, pump pocket infection, bloodstream infection and endocarditis/pump or cannula infection. Diagnostic evaluation and management of these complicated infections can be quite challenging for clinicians involved in the care of these patients. Here, the authors summarize the current epidemiology, microbiology, diagnostic approach and management strategies for each type of LVADRI. The authors also review current concepts regarding antibiotic prophylaxis for LVAD implantation. Finally, the authors highlight the gaps in the knowledge of LVADRI and provide directions for future studies.

[1]  R. Dowling,et al.  The future of adult cardiac assist devices: novel systems and mechanical circulatory support strategies. , 2011, Cardiology clinics.

[2]  Junchao Cai,et al.  Heart transplantation in the United States 2004. , 2004, Clinical transplants.

[3]  M H Samore,et al.  Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. , 2000, Circulation.

[4]  T. Guy,et al.  The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. , 2007, The Annals of thoracic surgery.

[5]  P. Malani,et al.  Fungemia Associated with Left Ventricular Assist Device Support , 2009, Journal of cardiac surgery.

[6]  P. McCarthy,et al.  Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. , 2001, The Annals of thoracic surgery.

[7]  P. Malani,et al.  Surgical Infection Prophylaxis for Left Ventricular Assist Device Implantation , 2011, Journal of cardiac surgery.

[8]  F. Lowy,et al.  Ventricular assist device-related infections. , 2006, The Lancet. Infectious diseases.

[9]  H. Matsuda,et al.  Successful treatment of Novacor pump pocket infection by omental transposition. , 2003, The Annals of thoracic surgery.

[10]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[11]  Bartley P Griffith,et al.  LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  Robert L Kormos,et al.  Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  Vikas Sharma,et al.  Driveline infections in left ventricular assist devices: implications for destination therapy. , 2012, The Annals of thoracic surgery.

[14]  J. Shuhaiber,et al.  Does the Type of Ventricular Assisted Device Influence Survival, Infection, and Rejection Rates Following Heart Transplantation? , 2009, Journal of cardiac surgery.

[15]  R. Michler,et al.  Right ventricular dysfunction following continuous flow left ventriccular assist device placement in 51 patients: predicators and outcomes , 2012, Journal of Cardiothoracic Surgery.

[16]  L. Køber,et al.  Driveline infections in patients supported with a HeartMate II: Incidence, aetiology and outcome , 2011, Scandinavian cardiovascular journal : SCJ.

[17]  B. Hota,et al.  Left ventricular assist device-related infection: treatment and outcome. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  P. Malani,et al.  Nosocomial infections in left ventricular assist device recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Takeshi Nakatani,et al.  Risk analysis of bloodstream infection during long-term left ventricular assist device support. , 2012, The Annals of thoracic surgery.

[20]  Allison R. Schulman,et al.  Effect of left ventricular assist device infection on post-transplant outcomes. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  Nader Moazami,et al.  Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. , 2007, The Annals of thoracic surgery.

[22]  Deborah Budge,et al.  Obesity and Left Ventricular Assist Device Driveline Exit Site Infection , 2010, ASAIO journal.

[23]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[24]  W. Holman Advances in Mechanical Circulatory Support Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) What Have We Learned and What Will We Learn? , 2012 .

[25]  M. Oz,et al.  Infections During Left Ventricular Assist Device Support Do Not Affect Posttransplant Outcomes , 2000, Circulation.

[26]  J. Tarrand,et al.  Differential Time to Positivity: A Useful Method for Diagnosing Catheter-Related Bloodstream Infections , 2004, Annals of Internal Medicine.

[27]  D. Warren,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Klaus Affeld,et al.  The effect of surface roughness on activation of the coagulation system and platelet adhesion in rotary blood pumps. , 2007, Artificial organs.

[29]  Yoshifumi Naka,et al.  Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). , 2011, Journal of the American College of Cardiology.

[30]  Marvin A. Konstam,et al.  Emerging ventricular assist devices for long-term cardiac support , 2010, Nature Reviews Cardiology.

[31]  Sean Pinney,et al.  Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  G. Trenholme,et al.  Infectious complications in left ventricular assist device recipients. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  G. Couper,et al.  Infection in permanent circulatory support: experience from the REMATCH trial. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  A. Montalto,et al.  Heartmate II axial-flow left ventricular assist system: management, clinical review and personal experience , 2009, Journal of cardiovascular medicine.

[35]  P M Portner,et al.  Mechanical Circulatory Support for Advanced Heart Failure: Effect of Patient Selection on Outcome , 2001, Circulation.

[36]  Keshava Rajagopal,et al.  Left ventricular assist device destination therapy versus extended criteria cardiac transplant. , 2010, The Annals of thoracic surgery.

[37]  H. Scheld,et al.  Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. , 1997, Circulation.

[38]  Nader Moazami,et al.  Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. , 2010, The Annals of thoracic surgery.

[39]  M. Oz,et al.  Fungal left ventricular assist device endocarditis. , 2001, The Annals of thoracic surgery.

[40]  M. Oz,et al.  Fungal Infections in Left Ventricular Assist Device Recipients: Incidence, Prophylaxis, and Treatment , 1995, ASAIO journal.

[41]  Diagnostic guidelines for Kawasaki disease. American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease. , 1990, American journal of diseases of children.

[42]  Ashish S Shah,et al.  Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[43]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[44]  M. Hannan,et al.  Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[45]  J. Goldstein,et al.  Percutaneous mechanical support for the failing right heart. , 2012, Cardiology clinics.

[46]  P. Grossi,et al.  Infectious complications in patients with the Novacor left ventricular assist system. , 2001, Transplantation proceedings.

[47]  C. Brun-Buisson,et al.  Nosocomial infections occurring during receipt of circulatory support with the paracorporeal ventricular assist system. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Walter R Wilson,et al.  Nonvalvular Cardiovascular Device–Related Infections , 2003, Circulation.

[49]  F. Pagani,et al.  Multicenter Experience: Prevention and Management of Left Ventricular Assist Device Infections , 2005, ASAIO journal.

[50]  W L Holman,et al.  Cost-Benefit Analysis of Extended Antifungal Prophylaxis in Ventricular Assist Devices , 2000, ASAIO journal.

[51]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[52]  J. Kors,et al.  Prevalence and Prognostic Significance of Heart Failure Stages: Application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the Community , 2007, Circulation.